| First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014 | 3565 | 2014 |
| Cisplatin-based adjuvant chemotherapy in patients with completely resected non–small-cell lung cancer International Adjuvant Lung Cancer Trial Collaborative Group New England Journal of Medicine 350 (4), 351-360, 2004 | 3002 | 2004 |
| Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter … T Le Chevalier, D Brisgand, JY Douillard, JL Pujol, V Alberola, A Monnier, ... Journal of Clinical Oncology 12 (2), 360-367, 1994 | 1143 | 1994 |
| Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) F Barlesi, J Mazieres, JP Merlio, D Debieuvre, J Mosser, H Lena, ... The Lancet 387 (10026), 1415-1426, 2016 | 932 | 2016 |
| Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non … L Paz-Ares, F de Marinis, M Dediu, M Thomas, JL Pujol, P Bidoli, ... The lancet oncology 13 (3), 247-255, 2012 | 770 | 2012 |
| PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin … LG Paz-Ares, F de Marinis, M Dediu, M Thomas, JL Pujol, P Bidoli, ... Journal of clinical oncology 31 (23), 2895-2902, 2013 | 731 | 2013 |
| Survival of patients with resected N2 non–small-cell lung cancer: evidence for a subclassification and implications F Andre, D Grunenwald, JP Pignon, A Dujon, JL Pujol, PY Brichon, ... Journal of clinical oncology 18 (16), 2981-2989, 2000 | 612 | 2000 |
| Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix, L Paz-Ares, CH Chiu, ... The Lancet Oncology 20 (12), 1655-1669, 2019 | 510 | 2019 |
| Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer JL Pujol, J Grenier, JP Daurès, A Daver, H Pujol, FB Michel Cancer research 53 (1), 61-66, 1993 | 473 | 1993 |
| Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind … JF Vansteenkiste, BC Cho, T Vanakesa, T De Pas, M Zielinski, MS Kim, ... The lancet oncology 17 (6), 822-835, 2016 | 469 | 2016 |
| Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer JR Eckardt, J von Pawel, JL Pujol, Z Papai, E Quoix, A Ardizzoni, R Poulin, ... Journal of Clinical Oncology 25 (15), 2086-2092, 2007 | 449 | 2007 |
| Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes T Le Chevalier, G Scagliotti, R Natale, S Danson, R Rosell, R Stahel, ... Lung cancer 47 (1), 69-80, 2005 | 408 | 2005 |
| Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this … JL Pujol, JP Daurès British journal of cancer 83 (1), 8-15, 2000 | 383 | 2000 |
| Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non–small-cell lung cancer JC Soria, Z Márk, P Zatloukal, B Szima, I Albert, E Juhász, JL Pujol, ... Journal of Clinical Oncology 29 (33), 4442-4451, 2011 | 286 | 2011 |
| Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer J von Pawel, U Gatzemeier, JL Pujol, L Moreau, S Bildat, M Ranson, ... Journal of clinical oncology 19 (6), 1743-1749, 2001 | 268 | 2001 |
| CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients JL Pujol, O Molinier, W Ebert, JP Daures, F Barlesi, G Buccheri, ... British Journal of Cancer 90 (11), 2097-2105, 2004 | 258 | 2004 |
| Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours W Jacot, D Bessis, E Jorda, M Ychou, M Fabbro, JL Pujol, B Guillot British Journal of Dermatology 151 (1), 238-241, 2004 | 231 | 2004 |
| A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index B Colinet, W Jacot, D Bertrand, S Lacombe, MC Bozonnat, JP Daures, ... British journal of cancer 93 (10), 1098-1105, 2005 | 230 | 2005 |
| Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients JL Pujol, JM Boher, J Grenier, X Quantin Lung cancer 31 (2-3), 221-231, 2001 | 229 | 2001 |
| Carcinoid tumors of the lung: do atypical features require aggressive management? CH Marty-Ané, V Costes, JL Pujol, M Alauzen, P Baldet, H Mary The Annals of thoracic surgery 59 (1), 78-83, 1995 | 224 | 1995 |
